• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Incident Ocular Diseases Related to Chemotherapy in Cancer Patients are Associated with Increasing Risk of Incident Stroke
CONCLUSIONS: Incident ocular diseases related to chemotherapy were associated with a significantly higher risk of stroke.PMID:37229341 | PMC:PMC10203719 | DOI:10.6515/ACS.202305_39(3).20221005A
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Kai-Chun Cheng Hung-Pin Tu Tsung-Hsien Lin Kai-Hung Cheng Source Type: research

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.PMID:34265496 | DOI:10.1016/j.breast.2021.07.004
Source: Breast - July 15, 2021 Category: Cancer & Oncology Authors: Maria Sund Miguel Garcia-Argibay Hans Garmo Johan Ahlgren Anna-Karin Wennstig Irma Fredriksson Henrik Lindman Antonis Valachis Source Type: research

Cancers, Vol. 13, Pages 2254: Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
Conclusions: Adjuvant therapy with AI in breast cancer women aged more than 50 years is associated with increased risk of heart failure and combined CV events.
Source: Cancers - May 8, 2021 Category: Cancer & Oncology Authors: Matteo Franchi Roberta Tritto Luigi Tarantini Alessandro Navazio Giovanni Corrao Tags: Article Source Type: research

Abstract PD4-07: Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study
Conclusions: The occurrence of MI is very low in this cohort (4.4%), reassuring the clinicians that the older adults with comorbidities may not be at a higher risk of MI with adjuvant endocrine therapy. However, the confidence interval for the hazard ratio of AIs vs Tamoxifen is very wide, indicating that a larger sample may be needed for the power of the study to be conclusive.Citation Format: Kamaraju S, Smith E, Shi Y, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study [abstract]. In: Proceedings of the Thirty-Ninth Annual C...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: S Kamaraju, E Smith, Y Shi, P Laud, J Neuner Tags: Poster Discussion Abstracts Source Type: research

Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))
Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC wer...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: K Hannebicque, L Boulanger, E Bogart, S Giard, MP Chauvet, JL Houpeau Tags: Poster Session Abstracts Source Type: research

Update on Breast Cancer Risk Reduction Therapy
Abstract In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prol...
Source: Current Breast Cancer Reports - July 19, 2016 Category: Cancer & Oncology Source Type: research

No increased risk of fatal CV events for breast cancer patients on newer hormone therapy
(Kaiser Permanente) In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke.
Source: EurekAlert! - Cancer - April 21, 2016 Category: Cancer & Oncology Source Type: news

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

Abstract PD4-2: Cardiovascular toxicity following aromatase inhibitor use in 13,273 survivors cared for in a HMO
Discussion These results indicate that variation exists in the type of CVD events that occur in breast cancer patients receiving AIs in comparison to tamoxifen users. For example, the risk of ischemic disease or stroke was not elevated in those who used AIs only versus TAM users. However, overall CVD events were greater in women who used AIs only (or sequentially after TAM), especially if they received left-sided breast irradiation. While these observational study results require cautious interpretation, they provide a basis for comparing the benefits and risks of endocrine treatments. Citation Format: Reina Haque, Joanne ...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Haque, R., Schottinger, J. E., Shi, J., Chung, J., Avila, C., Amundsen, B., Chlebowski, R. T. Tags: Poster Discussion Abstracts Source Type: research

Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention.
Source: JNCI - December 3, 2014 Category: Cancer & Oncology Authors: Nichols, H. B., DeRoo, L. A., Scharf, D. R., Sandler, D. P. Tags: Article Source Type: research

1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer
Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Chang, M. Tags: prevention and screening Source Type: research